Stay updated on Tivozanib vs Sorafenib in Refractory RCC Clinical Trial

Sign up to get notified when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The page now shows a new revision number (v3.6.3) replacing the previous v3.6.2, indicating a page update. This update does not alter study content or eligibility criteria.
    Difference
    0.0%
    Check dated 2026-07-06T16:31:01.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The page revision tag changed from v3.6.0 to v3.6.2, signaling a newer build/version of the page. This reflects an update to the page infrastructure rather than alterations to study content.
    Difference
    0.0%
    Check dated 2026-06-29T08:28:17.000Z thumbnail image
  4. Check
    34 days ago
    Change Detected
    Summary
    The page now displays 'No longer looking for participants' and standardizes the header to Intervention/Treatment, signaling that recruitment has closed. The page revision was updated to v3.6.0 and new help/navigation items (How to Read a Study Record, Common Questions, How to Join a Study) were added.
    Difference
    0.2%
    Check dated 2026-06-14T17:37:18.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Revision tag updated from v3.5.4 to v3.5.5, reflecting a new release version displayed on the page. The update is administrative and does not change study data, eligibility criteria, or how users interact with the page.
    Difference
    0.0%
    Check dated 2026-06-07T07:59:48.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    The page revision stamp changed from v3.5.3 to v3.5.4, indicating a small patch or metadata update rather than a substantive change to the page content.
    Difference
    0.0%
    Check dated 2026-05-16T19:57:16.000Z thumbnail image
  7. Check
    78 days ago
    Change Detected
    Summary
    A new publication citation has been added to the Publications section: Beckermann KE, Asnis-Alibozek AG, Atkins MB, Escudier B, Hutson TE, Kasturi V, McDermott DF, Pal SK, Porta C, Rini BI, Verzoni E. Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial. Oncologist. 2024 Mar 4;29(3):254-262. doi: 10.1093/oncolo/oyad348. This update expands the study's literature references related to outcomes in relapsed/refractory RCC treated with tivozanib.
    Difference
    0.0%
    Check dated 2026-05-02T09:55:45.000Z thumbnail image

Stay in the know with updates to Tivozanib vs Sorafenib in Refractory RCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.